3-(2,2,2-三氟乙酰氨基)苯基硼酸 | 88978-20-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2,2,2-三氟乙酰氨基)苯基硼酸
• 中文别名: 3-(2,2,2-三氟乙酰氨基)苯硼酸；B-[3-[(2,2,2-三氟乙酰基)氨基]苯基]硼酸
• 英文名称: 3-(2,2,2-trifluoroacetamido)phenylboronic acid
• 英文别名: 3-(2,2,2-trifluroacetamide)phenylboronic acid；(3-(2,2,2-Trifluoroacetamido)phenyl)boronic acid；[3-[(2,2,2-trifluoroacetyl)amino]phenyl]boronic acid
• CAS: 88978-20-5
• 化学式: C₈H₇BF₃NO₃
• mdl: MFCD08235083
• 分子量: 232.955
• InChiKey: NCOITLDGNKHMSB-UHFFFAOYSA-N

物化性质

• 熔点：
  290-293
• 密度：
  1.45

计算性质

• 辛醇/水分配系数(LogP)：
  2.08
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2931900090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-(2,2,2-Trifluoroacetamido)phenylboronic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-(2,2,2-Trifluoroacetamido)phenylboronic acid
Ingredient name:
CAS number: 88978-20-5

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C8H7BF3NO3
Molecular weight: 233.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-甲基-2-环己烯-1-酮 、 3-(2,2,2-三氟乙酰氨基)苯基硼酸 在 ammonium hexafluorophosphate 、 palladium(II) trifluoroacetate 、 水 、 (S)-4-叔丁基-2-(2-氮苯基)恶唑啉 作用下， 以 1,2-二氯乙烷 为溶剂， 以60%的产率得到(R)-3-(3-(2,2,2-trifluoroacetamide)phenyl)-3-methylcyclohexanone
  参考文献：
  名称：

  通过钯催化芳基硼酸与环烯酮的不对称共轭加成合成多种β-季酮

  摘要：

  描述了钯催化芳基硼酸与环烯酮共轭受体的不对称共轭加成的开发和优化。这些反应采用空气稳定且易于获得的试剂，通过操作简单且稳健的转化，以高产率和对映选择性产生 β-季酮。值得注意的是，反应本身对大气中的氧气和湿气具有高度耐受性，因此不需要使用干燥或脱氧溶剂、特别纯化的试剂或惰性气氛。烯酮的环大小和β-取代基变化很大，可以合成多种β-季酮。最近，NH 4 PF 6的使用进一步扩大了底物范围，包括含杂原子的芳基硼酸和β-酰基烯酮底物。

  DOI：

  10.1016/j.tet.2014.11.048
• 作为产物：
  描述：

  N-(3-bromophenyl)-2,2,2-trifluoroacetamide 在 正丁基锂 、 硼酸三异丙酯 、 盐酸 、 水 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 4.17h， 以67%的产率得到3-(2,2,2-三氟乙酰氨基)苯基硼酸
  参考文献：
  名称：

  通过钯催化芳基硼酸与环烯酮的不对称共轭加成合成多种β-季酮

  摘要：

  描述了钯催化芳基硼酸与环烯酮共轭受体的不对称共轭加成的开发和优化。这些反应采用空气稳定且易于获得的试剂，通过操作简单且稳健的转化，以高产率和对映选择性产生 β-季酮。值得注意的是，反应本身对大气中的氧气和湿气具有高度耐受性，因此不需要使用干燥或脱氧溶剂、特别纯化的试剂或惰性气氛。烯酮的环大小和β-取代基变化很大，可以合成多种β-季酮。最近，NH 4 PF 6的使用进一步扩大了底物范围，包括含杂原子的芳基硼酸和β-酰基烯酮底物。

  DOI：

  10.1016/j.tet.2014.11.048

文献信息

• Palladium-Catalyzed Asymmetric Conjugate Addition of Arylboronic Acids to Heterocyclic Acceptors
  作者：Jeffrey C. Holder、Alexander N. Marziale、Michele Gatti、Bin Mao、Brian M. Stoltz

  DOI：10.1002/chem.201203643

  日期：2013.1.2

  Flava Flavanone: Asymmetric conjugate additions to chromones and 4‐quinolones are reported utilizing a single catalyst system formed in situ from Pd(OCOCF3)2 and (S)‐tBuPyOX. Notably, these reactions are performed in wet solvent under ambient atmosphere, and employ readily available arylboronic acids as the nucleophile, thus providing ready access to these asymmetric heterocycles (see scheme).

  Flava 黄烷酮：据报道，使用由 Pd(OCOCF 3 ) 2和 ( S ) -t BuPyOX原位形成的单一催化剂体系，不对称共轭加成到色酮和 4-喹诺酮。值得注意的是，这些反应是在环境气氛下在湿溶剂中进行的，并使用容易获得的芳基硼酸作为亲核试剂，从而提供了对这些不对称杂环的快速访问（参见方案）。
• [EN] COMPOUNDS FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY<br/>[FR] COMPOSÉS DESTINÉS AU TRAITEMENT DE LA DYSTROPHIE MUSCULAIRE DE DUCHENNE
  申请人：BIOMARIN IGA LTD

  公开号：WO2010069684A1

  公开（公告）日：2010-06-24

  Compounds of formula (I): wherein R1, R2, X1, and X2 are as defined herein, are useful for the treatment or prophylaxis of conditions such as Duchenne muscular dystrophy, Becker muscular dystrophy, and cachexia.

  式(I)的化合物：其中R1、R2、X1和X2如本文所定义，可用于治疗或预防杜兴氏肌肉萎缩症、贝克氏肌肉萎缩症和消瘦症等疾病。
• Biphenyl Gal and GalNAc FmlH Lectin Antagonists of Uropathogenic <i>E. coli</i> (UPEC): Optimization through Iterative Rational Drug Design
  作者：Amarendar Reddy Maddirala、Roger Klein、Jerome S. Pinkner、Vasilios Kalas、Scott J. Hultgren、James W. Janetka

  DOI：10.1021/acs.jmedchem.8b01561

  日期：2019.1.24

  The F9/Yde/Fml pilus, tipped with the FmlH adhesin, has been shown to provide uropathogenic Escherichia coli (UPEC) a fitness advantage in urinary tract infections (UTIs). Here, we used X-ray structure guided design to optimize our previously described ortho-biphenyl Gal and GalNAc FmlH antagonists such as compound 1 by replacing the carboxylate with a sulfonamide as in 50. Other groups which can accept H-bonds were also tolerated. We pursued further modifications to the biphenyl aglycone resulting in significantly improved activity. Two of the most potent compounds, 86 (IC50 = 0.051 mu M) and 90 (IC50 = 0.034 mu M), exhibited excellent metabolic stability in mouse plasma and liver microsomes but showed only limited oral bioavailability (<1%) in rats. Compound 84 also showed a good pharmacokinetic (PK) profile in mice after IP dosing with compound exposure above the IC50 for 6 h. These new FmlH antagonists represent new antivirulence drugs for UTIs.
• Synthesis of diverse β-quaternary ketones via palladium-catalyzed asymmetric conjugate addition of arylboronic acids to cyclic enones
  作者：Jeffrey C. Holder、Emmett D. Goodman、Kotaro Kikushima、Michele Gatti、Alexander N. Marziale、Brian M. Stoltz

  DOI：10.1016/j.tet.2014.11.048

  日期：2015.9

  The development and optimization of a palladium-catalyzed asymmetric conjugate addition of arylboronic acids to cyclic enone conjugate acceptors is described. These reactions employ air-stable and readily-available reagents in an operationally simple and robust transformation that yields β-quaternary ketones in high yields and enantioselectivities. Notably, the reaction itself is highly tolerant of

  描述了钯催化芳基硼酸与环烯酮共轭受体的不对称共轭加成的开发和优化。这些反应采用空气稳定且易于获得的试剂，通过操作简单且稳健的转化，以高产率和对映选择性产生 β-季酮。值得注意的是，反应本身对大气中的氧气和湿气具有高度耐受性，因此不需要使用干燥或脱氧溶剂、特别纯化的试剂或惰性气氛。烯酮的环大小和β-取代基变化很大，可以合成多种β-季酮。最近，NH 4 PF 6的使用进一步扩大了底物范围，包括含杂原子的芳基硼酸和β-酰基烯酮底物。